Actavis, Inc.

Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 JUPITER, Fla. & DURHAM, N.C.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer. This press release features multimedia. View the full release here: Scott Plesha, CEO, Pelthos Therapeutics (Photo: Business Wire) Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company’s lead product is ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.1 ZELSUVMI has received a Novel Drug designation from the U.S. Food and Drug Administration and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using Pelthos’ proprietary nitric oxide-based technology platform, NITRICIL™. ZELSUVMI is expected to be available in the United States in late 2024. Ligand acquired the rights to ZELSUVMI and all the assets related to the NITRICIL technology platform from Novan, Inc. in September 2023. “ZELSUVMI is a highly differentiated product that we believe will bring significant improvements to the lives of patients living with tremendous unmet needs,” said Todd Davis, CEO of Ligand. “We are excited for the launch of Pelthos, the commercialization of ZELSUVMI, and the advancement of the company under Scott’s leadership.” Mr. Plesha brings to his role more than 30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharmaceutical commercial organizations. Prior to joining Pelthos, Mr. Plesha was President and Chief Commercial Officer at BioDelivery Sciences (BDSI) until it was acquired by Collegium Pharmaceutical in 2022. Under Mr. Plesha’s leadership, BDSI sales grew from $5 million to $160 million. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During his fifteen-year tenure at Salix, Mr. Plesha led a nationwide salesforce that grew product sales to more than $1.5 billion annually. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals. “I am excited to assume the leadership of Pelthos as we prepare to offer the first at-home therapy for the many patients who are completely untreated today or who need a more suitable option,” said Scott Plesha. “This is a company that has several meaningful milestones on the horizon and a team that is ready to execute to meet the needs of patients.” Ligand intends to commercialize ZELSUVMI in partnership with a capital provider and/or strategic partner. This is consistent with Ligand’s strategy to reposition and maximize the value of highly differentiated and promising pharmaceutical assets by combining premier management teams and outside funding sources in return for significant equity and royalty rights in the newly formed entities. To date, Ligand has created three companies utilizing this strategy: Viking Therapeutics, Primrose Bio, and OmniAb®. Pelthos is a wholly owned subsidiary of Ligand. About ZELSUVMI™ (berdazimer) topical gel, 10.3% ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. Complete prescribing information is available at . About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit . Follow Ligand on X @Ligand_LGND. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. About Pelthos Therapeutics Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. Our lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum is now approved by the U.S. Food and Drug Administration. In addition to ZELSUVMI, Pelthos has a pipeline of potential product candidates that utilize our proprietary nitric oxide-based technology platform, NITRICIL™. More information is available at . Follow Pelthos on LinkedIn and X. Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include: the timing of commercial launch of ZELSUVMI; the potential that ZELSUVMI could avoid surgical removal or more intensive therapies in some patients; and the possibility that Ligand’s strategy to maximize value through the creation of Pelthos Therapeutics will be successful. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand’s business, including, without limitation: the risk that Ligand and Pelthos may not commercially launch ZELSUVMI in late 2024 or at all; Ligand and Pelthos may not be able to successfully commercialize ZELSUVMI which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; the market size for ZELSUVMI may be smaller than estimated; Ligand’s dependence on third parties in connection with product manufacturing and distribution of ZELSUVMI; Ligand may not be able to protect its intellectual property and patents covering ZELSUVMI which may be challenged or invalidated; and other risks described in Ligand’s prior press releases and filings with the Securities and Exchange Commission available at . Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. __________________________ 1 ZELSUVMI Package Insert. LNHC Inc. 2023.

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. He will continue to report to Dr. Sharon Mates, Chairman and Chief Executive Officer. “Michael is an exceptional leader who has been instrumental in Intra-Cellular Therapies’ strong growth over the last decade,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “His knowledge of the Company and broad industry experience has contributed to our success and helped to establish our strong foundation for future growth. I look forward to continuing to work with him in his new role as we further build on our commercial success and advance our broad pipeline.” Mr. Halstead is a seasoned healthcare executive, with deep experience in various aspects of the biopharmaceutical industry. He joined Intra-Cellular Therapies in 2014 as Senior Vice President and General Counsel and was promoted to Executive Vice President and General Counsel in 2019. During his tenure, he has assumed increasing oversight responsibilities for many company functions. Prior to joining Intra-Cellular Therapies, Mr. Halstead served in leadership roles at Warner Chilcott plc, including Senior Vice President, Corporate Development, where he directed the company’s corporate development, legal and human resources functions. Prior to that, Mr. Halstead was an attorney with Davis Polk & Wardwell. Intra-Cellular Therapies also announced that Senior Vice President and Chief Financial Officer, Larry Hineline, will be retiring after more than 20 years of service. Mr. Hineline has served as Chief Financial Officer since June 2002. The Company has initiated an external search for a new Chief Financial Officer and Mr. Hineline has agreed to remain with the Company through the process to ensure a smooth transition. “I am grateful for Larry’s significant contributions over the years as ITCI evolved from a private company to the fully integrated public biopharmaceutical company it is today,” said Dr. Mates. “On behalf of the Board and the entire company we thank him for his dedication and wish him all the best in his well-deserved retirement.” About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit . Contact: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333 Burns McClellan, Inc. Cameron Radinovic cradinovic@burnsmc.com 646-930-4406

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday. This prestigious award highlights Mr. McEnany's outstanding accomplishments, unwavering commitment to rare disease patients, dedication to Catalyst’s employees, and pivotal role in fostering the growth of Florida's biopharmaceutical ecosystem. "I extend my heartfelt gratitude to BioFlorida for bestowing this distinguished honor and recognition upon me. Guiding Catalyst's transformation from a modest startup into a thriving enterprise has been a source of immense fulfillment,” stated Mr. McEnany, Founder, Chairman, and CEO of Catalyst. “Our unwavering commitment to the rare-disease patient community that we serve has been the driving force behind our Company's success, fueled by the collective contributions of all of our Catalyst team members. I am profoundly thankful to all who have been a part of my remarkable journey." "It is our pleasure to celebrate Patrick McEnany’s illustrious career and contribution to Florida’s economic development through BioFlorida’s 2023 Lifetime Achievement Award,” said Nancy K. Bryan, President and CEO of BioFlorida. “Through his work and accomplishments, Mr. McEnany has profoundly impacted not only his immediate local community in Coral Gables but also the broader state of Florida. We are thrilled to recognize his remarkable contributions to the field of rare diseases, symbolizing his unwavering dedication to improving the lives of those facing these challenging medical conditions.” This award recognizes Mr. McEnany's visionary leadership and significant contributions as a distinguished co-founder, Chairman, President, and Chief Executive Officer of Catalyst. Since the Company’s inception in January 2002, Mr. McEnany has been at the helm, serving as CEO and a dedicated member of the Company’s board of directors. His pivotal roles as Chairman and President were assumed in March 2006, marking an important milestone in his leadership journey. Prior to founding Catalyst, Mr. McEnany was previously the Chairman and CEO at Royce Laboratories, Inc., a Miami-based generic pharmaceutical manufacturer, from 1991 to 1997. Following the merger of Royce Laboratories into Watson Pharmaceuticals, Inc., Mr. McEnany continued to play an instrumental role, serving as the President of the wholly owned Royce Laboratories subsidiary of Watson, as well as Vice President of Corporate Development for Watson until 1999. During his tenure, he also assumed the role of Vice Chairman and Director at the National Association of Pharmaceutical Manufacturers from 1993 to 1997. Mr. McEnany's unwavering commitment to the community is reflected in his active involvement in philanthropic initiatives. He currently serves on the emeritus board of directors of the Jackson Health Foundation and the board of directors of the Humane Society of Greater Miami. Over the last three decades, he has provided his expertise as a director to numerous public companies, contributing his extensive knowledge and leadership acumen to their growth and success. About Catalyst PharmaceuticalsWith exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst's flagship U.S. commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Finally, on July 18, 2023, Catalyst acquired an exclusive license for North America for vamorolone, a promising best-in-class dissociative anti-inflammatory steroid treatment for Duchenne Muscular Dystrophy. Vamorolone has received FDA Orphan Drug and Fast Track designations and has been granted a PDUFA action date of October 26, 2023. For more information about Catalyst Pharmaceuticals, Inc., visit the Company's website at www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE®, visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit www.fycompa.com. Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. Source: Catalyst Pharmaceuticals, Inc.